233 related articles for article (PubMed ID: 19642998)
1. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.
Zhou J; Goh BC; Albert DH; Chen CS
J Hematol Oncol; 2009 Jul; 2():33. PubMed ID: 19642998
[TBL] [Abstract][Full Text] [Related]
2. Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition.
Franklin PH; Banfor PN; Tapang P; Segreti JA; Widomski DL; Larson KJ; Noonan WT; Gintant GA; Davidsen SK; Albert DH; Fryer RM; Cox BF
J Pharmacol Exp Ther; 2009 Jun; 329(3):928-37. PubMed ID: 19255283
[TBL] [Abstract][Full Text] [Related]
3. Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer.
Chen J; Guo J; Chen Z; Wang J; Liu M; Pang X
Sci Rep; 2016 Jul; 6():29382. PubMed ID: 27387652
[TBL] [Abstract][Full Text] [Related]
4. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.
Albert DH; Tapang P; Magoc TJ; Pease LJ; Reuter DR; Wei RQ; Li J; Guo J; Bousquet PF; Ghoreishi-Haack NS; Wang B; Bukofzer GT; Wang YC; Stavropoulos JA; Hartandi K; Niquette AL; Soni N; Johnson EF; McCall JO; Bouska JJ; Luo Y; Donawho CK; Dai Y; Marcotte PA; Glaser KB; Michaelides MR; Davidsen SK
Mol Cancer Ther; 2006 Apr; 5(4):995-1006. PubMed ID: 16648571
[TBL] [Abstract][Full Text] [Related]
5. ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft.
Jasinghe VJ; Xie Z; Zhou J; Khng J; Poon LF; Senthilnathan P; Glaser KB; Albert DH; Davidsen SK; Chen CS
J Hepatol; 2008 Dec; 49(6):985-97. PubMed ID: 18930332
[TBL] [Abstract][Full Text] [Related]
6. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
[TBL] [Abstract][Full Text] [Related]
7. In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor.
Zhou J; Khng J; Jasinghe VJ; Bi C; Neo CH; Pan M; Poon LF; Xie Z; Yu H; Yeoh AE; Lu Y; Glaser KB; Albert DH; Davidsen SK; Chen CS
Leuk Res; 2008 Jul; 32(7):1091-100. PubMed ID: 18160102
[TBL] [Abstract][Full Text] [Related]
8. Linifanib: current status and future potential in cancer therapy.
Aversa C; Leone F; Zucchini G; Serini G; Geuna E; Milani A; Valdembri D; Martinello R; Montemurro F
Expert Rev Anticancer Ther; 2015 Jun; 15(6):677-87. PubMed ID: 25936222
[TBL] [Abstract][Full Text] [Related]
9. ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models.
Jiang F; Albert DH; Luo Y; Tapang P; Zhang K; Davidsen SK; Fox GB; Lesniewski R; McKeegan EM
J Pharmacol Exp Ther; 2011 Jul; 338(1):134-42. PubMed ID: 21505059
[TBL] [Abstract][Full Text] [Related]
10. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies.
Wong CI; Koh TS; Soo R; Hartono S; Thng CH; McKeegan E; Yong WP; Chen CS; Lee SC; Wong J; Lim R; Sukri N; Lim SE; Ong AB; Steinberg J; Gupta N; Pradhan R; Humerickhouse R; Goh BC
J Clin Oncol; 2009 Oct; 27(28):4718-26. PubMed ID: 19720910
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway.
Zhou J; Pan M; Xie Z; Loh SL; Bi C; Tai YC; Lilly M; Lim YP; Han JH; Glaser KB; Albert DH; Davidsen SK; Chen CS
Leukemia; 2008 Jan; 22(1):138-46. PubMed ID: 17943175
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Horinouchi H; Yamamoto N; Nokihara H; Horai T; Nishio M; Ohyanagi F; Horiike A; Nakagawa K; Terashima M; Okabe T; Kaneda H; McKee MD; Carlson DM; Xiong H; Tamura T
Cancer Chemother Pharmacol; 2014 Jul; 74(1):37-43. PubMed ID: 24807459
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.
Guo J; Marcotte PA; McCall JO; Dai Y; Pease LJ; Michaelides MR; Davidsen SK; Glaser KB
Mol Cancer Ther; 2006 Apr; 5(4):1007-13. PubMed ID: 16648572
[TBL] [Abstract][Full Text] [Related]
16. A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model.
Luo Y; Jiang F; Cole TB; Hradil VP; Reuter D; Chakravartty A; Albert DH; Davidsen SK; Cox BF; McKeegan EM; Fox GB
Cancer Chemother Pharmacol; 2012 Apr; 69(4):911-21. PubMed ID: 22080168
[TBL] [Abstract][Full Text] [Related]
17. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
18. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Smolle E; Taucher V; Petru E; Haybaeck J
Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
[TBL] [Abstract][Full Text] [Related]
19. ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways.
Ikeda AK; Judelson DR; Federman N; Glaser KB; Landaw EM; Denny CT; Sakamoto KM
Mol Cancer Ther; 2010 Mar; 9(3):653-60. PubMed ID: 20197394
[TBL] [Abstract][Full Text] [Related]
20. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.
Shankar DB; Li J; Tapang P; Owen McCall J; Pease LJ; Dai Y; Wei RQ; Albert DH; Bouska JJ; Osterling DJ; Guo J; Marcotte PA; Johnson EF; Soni N; Hartandi K; Michaelides MR; Davidsen SK; Priceman SJ; Chang JC; Rhodes K; Shah N; Moore TB; Sakamoto KM; Glaser KB
Blood; 2007 Apr; 109(8):3400-8. PubMed ID: 17209055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
